Bengaluru: Healthcare Global Enterprise Limited (HCG) reported a 13 per cent increase in year on year (YoY) revenue to Rs 695.1 crore in the quarter ended June this year.
The cancer specialist hospital said its North Bangalore hospital commenced operations in May 2026, contributing to Rs 6.7 crore in revenue.
Adjusted ebitda stood at Rs 133.9 crore, up 20 per cent YoY, while ebitda margins improved 19.4 per cent compared to 18.2 per cent in Q1FY26.
HCG said growth in the quarter was driven by volume growth of 11 per cent YoY, while ARPP increased by 2 percent YoY driven by a favourable payor mix which was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies.
Its international business revenue was Rs 20.8 crore, up approximately 9 per cent YoY driven by stronger patient inflows for radiation oncology and PET cases.
Revenue for its fertility business which was divested in June 2026 stood at Rs 16.9 crore with ebitda for Rs 2.3 crore.
During the quarter, the healthcare chain commissioned a 120 plus bed hospital in North Bangalore, Hebbal.
A total of 121 operational beds were added comprising of 56 beds at North Bangalore, 26 beds at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya, further strengthening capacity across the network, HCG said.
Dr. Manish Mattoo, Executive Director & CEO, HCG, said, “We have started FY27 on a strong note, with revenue growing 13% year-on-year to ₹6,951 million. Excluding North Bangalore hospital, 16 of our 25 centres recorded their highest-ever quarterly revenues, reflecting broad-based growth across our network and sustained demand for our oncology services.”
“Our focus on increasing the share of high-complexity oncology care and non-institutional business continues to strengthen the quality of our revenue. Non-institutional revenue grew 17% year-on-year, with its contribution increasing from 67% to 69%, while Adjusted EBITDA, grew 20% to ₹1,339 million, with margins improving to 19.4%.”
